文献速递肿瘤 PET/CT

68Ga-PSMA-11 PET分期后根治性前列腺切除术肿瘤学结局改善:单中心回顾性队列比较

Improved oncological outcome after radical prostatectomy in patients staged with 68Ga-PSMA-11 PET: a single-center retrospective cohort comparison.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-10-19

PSMA组ISUP分级和D'Amico评分更高,但切缘阴性率和PSA持续率无显著差异;高危亚组中PSMA组术后PSA持续率显著更低(7% vs 25%,p=0.04)。

要点

  • PSMA-PET分期组整体风险更高,但术后切缘状态和PSA持续率未变差。
  • 高危亚组中PSMA-PET分期与术后PSA持续率显著降低相关(7% vs 25%,p=0.04)。
  • 回顾性设计且部分常规影像组患者曾用胆碱PET,结论需谨慎解读。

核心结论

  • PSMA-PET分期后行根治性前列腺切除术的即期肿瘤学结局不劣于常规影像分期,尽管PSMA组队列风险更高。
  • 仅比较高危患者时,PSMA-PET分期与术后PSA持续率显著降低相关。

研究设计与样本

  • 比较两组术前肿瘤学风险参数(年龄、PSA、D'Amico评分、穿刺ISUP分级、cT分期)及术后结局(PSA持续、神经保留率、手术切缘状态)。
  • 统计方法采用Wilcoxon秩和检验、Fisher检验和卡方检验。

主要发现

  • PSMA组ISUP分级更高(p < 0.001),D'Amico评分更高(p < 0.05)。
  • 常规影像组与PSMA组切缘阴性率分别为64%和77%(p = 0.15),PSA持续率分别为17%和6%(p = 0.13)。
  • 高危亚组中,PSMA组PSA持续率为7%(3/44),常规影像组为25%(7/28),差异显著(p = 0.04)。

关键数值与推荐

  • 高危亚组术后PSA持续率:PSMA-PET组7%(3/44) vs 常规影像组25%(7/28),p = 0.04。
  • 整体队列切缘阴性率:常规影像组64% vs PSMA组77%,p = 0.15。
  • 整体队列PSA持续率:常规影像组17% vs PSMA组6%,p = 0.13。

临床怎么用

  • 对于中高危前列腺癌患者,术前PSMA-PET分期可作为分层工具,不劣化根治性前列腺切除术的即期肿瘤学结局。
  • 高危患者术前PSMA-PET分期可能有助于降低术后PSA持续风险,但需前瞻性研究验证。

局限性

  • 回顾性设计。
  • 常规影像组部分患者使用了胆碱PET。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Positron emission tomography (PET) targeting the prostate-specific membrane antigen (PSMA) has superior sensitivity over conventional imaging (CI) to stage prostate cancer (PCa) and therefore is increasingly used in staging to stratify patients before radical therapy. Whether this improved diagnostic accuracy translates into improved outcome after radical prostatectomy (RPE) has not yet been shown. Therefore, the aim of this study was to compare the oncological outcome after RPE between patients that underwent preoperative staging with CI or PSMA-PET for intermediate and high-risk PCa. METHODS: We retrospectively selected all patients that underwent RPE for intermediate- or high-risk PCa at our institution before PSMA-PET introduction (between March 2014 and September 2016) and compared the oncologic outcome of patients staged with PSMA-PET (between October 2016 and October 2018). Oncological pre-surgical risk parameters (age, PSA, D'Amico score, biopsy-ISUP, and cT stage) were compared between the groups. Oncological outcome was determined as PSA persistence, nerve-sparing rate, and surgical margin status. Wilcoxon rank-sum, Fisher's, and chi-square tests where used for statistical testing. RESULTS: One hundred five patients were included, 53 in the CI group and 52 in the PSMA-group. Patients in the PSMA group had higher ISUP grade (p < 0.001) and D'Amico score (p < 0.05). The rate of free surgical margins and PSA persistence after RPE was 64% and 17% for the CI and 77% and 6% for the PSMA group (p = 0.15 and 0.13, respectively). Subgroup analysis with high-risk patients revealed PSA persistence in 7% (3/44) in the PSMA group and 25% (7/28) in the CI group (p = 0.04). Limitations include the retrospective design and choline-PET for some patients in the CI group. CONCLUSION: Immediate outcome after RPE was not worse in the PSMA group compared with the CI group, despite a higher-risk cohort. In a comparison of only high-risk patients, PSMA-PET staging was associated with a significantly lower rate of postsurgical PSA persistence.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ferraro DA, Lehner F, Becker AS, et al. Improved oncological outcome after radical prostatectomy in patients staged with 68Ga-PSMA-11 PET: a single-center retrospective cohort comparison. Eur J Nucl Med Mol Imaging. 2020. PMID: 33074376. doi:10.1007/s00259-020-05058-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。